Lipocine's 2025 Financial Report Highlights Pipeline Progress and Market Opportunities Lipocine Inc. shared its financial results for 2025, showcasing significant pipeline developments for mental health and metabolic disorders, setting the stage for future progress.

Lipocine's 2025 Financial Report Highlights Pipeline Progress and Market Opportunities #United_States #Salt_Lake_City #Lipocine #LPCN_1154 #TLANDO

Lipocine Reports Q3 2025 Financial Results and Clinical Updates Lipocine Inc. announces third quarter financial results for 2025 and updates on clinical trials, including LPCN 1154 for postpartum depression.

Lipocine Reports Q3 2025 Financial Results and Clinical Updates #USA #Salt_Lake_City #Lipocine #LPCN_1154 #TLANDO

Lipocine Reports Second Quarter Financial Results and Updates on Pivotal Studies Lipocine Inc. shares Q2 financial results and advancements on LPCN 1154, a treatment for postpartum depression, alongside updates on LPCN 2401.

Lipocine Reports Second Quarter Financial Results and Updates on Pivotal Studies #USA #Salt_Lake_City #Lipocine #LPCN_1154 #TLANDO

Lipocine's TLANDO® Submission Marks a New Era in TRT in Canada Lipocine Inc. announces a New Drug Submission for TLANDO® in Canada, aiming to meet the growing demand for testosterone replacement therapy.

Lipocine's TLANDO® Submission Marks a New Era in TRT in Canada #Canada #Salt_Lake_City #Lipocine #TLANDO #TRT

Lipocine to Showcase Innovative Therapeutics at A.G.P.'s Annual Healthcare Event Lipocine Inc. will present its advanced drug delivery technology at A.G.P.'s Annual Healthcare Company Showcase on May 21, 2025, highlighting promising therapeutic candidates.

Lipocine to Showcase Innovative Therapeutics at A.G.P.'s Annual Healthcare Event #United_States #NASDAQ #Salt_Lake_City #Lipocine #TLANDO

Lipocine Inc.: Key Financial Update and Future Developments as of Q1 2025 Lipocine Inc. announces its financial performance for Q1 2025, highlighting key developments and ongoing studies towards innovative treatments.

Lipocine Inc.: Key Financial Update and Future Developments as of Q1 2025 #United_States #Salt_Lake_City #LPCN_1154 #TLANDO #Lipocine_Inc

Lipocine Expands Presence in Brazil with TLANDO® Licensing Agreement Lipocine Inc. announces a new licensing agreement with Aché for TLANDO®, a testosterone therapy, aimed at tapping into Brazil's growing market for prescription testosterone products.

Lipocine Expands Presence in Brazil with TLANDO® Licensing Agreement #Brazil #São_Paulo #Lipocine #TLANDO #Aché